Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging
Erschienen in: Nuclear Medicine and Molecular Imaging 3/2019

29.01.2019 | Review

Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches

verfasst von: Makoto Hosono

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT is recently called molecular radiotherapy (MRT) by some advocators in order to emphasize its characteristics as radiotherapy and the relevance of dosimetry-guided optimization of treatment. Moreover, RNT requires relevant radiation protection standards because it employs unsealed radionuclides and gives therapeutic radiation doses in humans. On the basis of these radiation protection standards, the development and use of radiopharmaceuticals for combined application through diagnostics and therapeutics lead to theranostic approaches that will enhance the efficacy and safety of treatment by implementing dosimetry-based individualization.
Literatur
1.
2.
Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 2016;8:35–8.PubMedPubMedCentral
3.
Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58:97S–103S.CrossRefPubMed
4.
Stokke C, Gabina PM, Solny P, Cicone F, Sandstrom M, Gleisner KS, et al. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the internal dosimetry task force. EJNMMI Phys. 2017;4:27.CrossRefPubMedPubMedCentral
5.
Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.CrossRefPubMed
6.
Pryma DA, Mandel SJ. Radioiodine therapy for thyroid Cancer in the era of risk stratification and alternative targeted therapies. J Nucl Med. 2014;55:1485–91.CrossRefPubMed
7.
Luster M, Pfestroff A, Hanscheid H, Verburg FA. Radioiodine therapy. Semin Nucl Med. 2017;47:126–34.CrossRefPubMed
8.
Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology: VII. The use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.CrossRefPubMed
9.
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132:838–47.CrossRefPubMed
10.
Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for Radioimmunotherapy of non-Hodgkin’s lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–72.PubMed
11.
Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465–74.PubMed
12.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804–10.CrossRefPubMed
13.
Bexxar KM. Iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin’s lymphoma. Cancer Biol Ther. 2007;6:996–7.
14.
Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 2010;14:347–51.PubMed
15.
16.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMedPubMedCentral
17.
Strosberg J, Krenning E. 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:1391–2.CrossRefPubMed
18.
Hosono M, Ikebuchi H, Nakamura Y, Yanagida S, Kinuya S. Introduction of the targeted alpha therapy (with radium-223) into clinical practice in Japan: learnings and implementation. Ann Nucl Med. 2018 online first.
19.
Parker C, Heidenreich A, Nilsson S, Shore N. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018;21:37–47.CrossRefPubMedPubMedCentral
20.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefPubMed
21.
Hosono M. Radiation protection in therapy with radiopharmaceuticals. Int J Radiat Biol. 2018 online first.
22.
ICRP. The 2007 recommendations of the international commission on radiological protection. ICRP Publication 103. Ann ICRP. 2007;37:1–332.
23.
ICRP. ICRP publication 105. Radiation protection in medicine. Ann ICRP. 2007;37:1–63.
24.
ICRP. ICRP publication 94. Release of nuclear medicine patients after therapy with unsealed sources. Ann ICRP. 2004;34:1–79.
25.
Flux GD, Sjogreen Gleisner K, Chiesa C, Lassmann M, Chouin N, Gear J, et al. From fixed activities to personalized treatments in radionuclide therapy: lost in translation? Eur J Nucl Med Mol Imaging. 2018;45:152–4.CrossRefPubMed
26.
Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, et al. Clinical radionuclide therapy dosimetry: the quest for the “holy gray”. Eur J Nucl Med Mol Imaging. 2007;34:772–86.CrossRefPubMedPubMedCentral
27.
Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W. Dosimetry in clinical radionuclide therapy: the devil is in the detail. Eur J Nucl Med Mol Imaging. 2017;44:2137–9.CrossRefPubMed
28.
Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Bacher K, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017;44:1783–6.CrossRefPubMed
29.
Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, et al. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of Tsh stimulation and number of preceding radioiodine therapies. Ann Nucl Med. 2012;26:723–9.CrossRefPubMed
30.
Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96:3217–25.CrossRefPubMedPubMedCentral
31.
Verburg FA, Hanscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37:896–903.CrossRefPubMed
32.
Verburg FA, Luster M, Giovanella L, Lassmann M, Chiesa C, Chouin N, et al. The “reset button” revisited: why high activity (131)I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. Eur J Nucl Med Mol Imaging. 2017;44:915–7.CrossRefPubMed
33.
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.CrossRefPubMed
34.
Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58:83S–90S.CrossRefPubMed
35.
Choudhury P, Gupta M. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 2017;10:166–70.CrossRefPubMed
36.
Nitipir C, Niculae D, Orlov C, Barbu MA, Popescu B, Popa AM, et al. Update on radionuclide therapy in oncology. Oncol Lett. 2017;14:7011–5.PubMedPubMedCentral
37.
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.CrossRefPubMed
38.
Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56:1304–9.CrossRefPubMed
39.
Pratt BE, Hindorf C, Chittenden SJ, Parker CC, Excretion FGD. Whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer. Nucl Med Commun. 2018;39:125–30.PubMed
40.
41.
Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, et al. The potential of (223)Ra and (18)F-fluoride imaging to predict bone lesion response to treatment with (223)Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1832–44.CrossRefPubMedPubMedCentral
42.
Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32.CrossRefPubMed
43.
Minguez P, Gustafsson J, Flux G, Gleisner KS. Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with (131)I-MIBG. Phys Med Biol. 2016;61:2532–51.CrossRefPubMed
44.
Sjogreen Gleisner K, Spezi E, Solny P, Gabina PM, Cicone F, Stokke C, et al. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Phys. 2017;4:28.CrossRefPubMedPubMedCentral
45.
Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88.CrossRefPubMed
46.
Iagaru A, Gambhir SS, Goris ML. 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med. 2008;49:1809–12.CrossRefPubMed
47.
Hanaoka K, Hosono M, Tatsumi Y, Ishii K, Im SW, Tsuchiya N, et al. Heterogeneity of intratumoral (111)in-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma. EJNMMI Res. 2015;5:10.CrossRefPubMedPubMedCentral
48.
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.CrossRefPubMed
Metadaten
Titel
Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches
verfasst von
Makoto Hosono
Publikationsdatum
29.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 3/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00586-x

Weitere Artikel der Ausgabe 3/2019

Nuclear Medicine and Molecular Imaging 3/2019 Zur Ausgabe

Review

Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals

Case Report

Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE

Case Report

Ipsilateral Hyperhidrosis: Atypical Symptom of Small Lung Adenocarcinoma Evaluated by 18F-FDG PET-CT

Original Article

Lesion-Wise Comparison of Pre-Therapy and Post-Therapy Effective Half-Life of Iodine-131 in Pediatric and Young Adult Patients with Differentiated Thyroid Cancer Undergoing Radioiodine Therapy

Original Article

Use of Molecular Imaging in Clinical Drug Development: a Systematic Review

Perspective

Perspectives in Radiomics for Personalized Medicine and Theranostics